BMS, Pfizer secure victory over generic makers
07-08-2020
Kite must pay $1.2bn for infringing CAR-T patent
09-04-2020
Kite accused of infringing Juno’s cancer immunotherapy
05-09-2017
Sundry Photography / Shutterstock.com
A court has rejected Gilead’s attempt to overturn a $752 million verdict in a patent dispute with BMS’ Juno Therapeutics over CAR-T therapies.
You need a subscription to continue reading this content.
Start a subscription today to access the LSIPR website.
To access the full archive, digital magazines and special reports you will need to take out a paid subscription.
If you have already subscribed please login.
If you have any technical issues please email tech support.
For access to the complete website, archive, and to receive print publications, choose '12 MONTH SUBSCRIPTION'. For a free, two-week trial with full access, select ‘TWO WEEK FREE TRIAL’.
Gilead, BMS, Juno Therapeutics, Kite, CAR-T, immunotherapy, patent infringement,
